Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of Genotropin dose escalation for growth retardation prevention in children with systemic juvenile idiopathic arthritis on long-term corticosteroids
2014-004105-32Phase 3
- Sponsor
- Pfizer
- Start
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of somatropin in juvenile idiopathic arthritis (JIA) (2 arms), sponsored by Pfizer. Primary endpoint: Change from baseline in annual rate of growth standard deviation score.
02
Drugs
somatropin
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2014-004105-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004105-32.